Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
01.10. | Appili Therapeutics Inc: Appili, Vitalex win up to $40M (U.S.) VXV-01 contract | 1 | Stockwatch | ||
01.10. | Stocks in Play: Appili Therapeutics Inc. | 1 | Baystreet.ca | ||
01.10. | Appili receives $3.6 million NIAID contract for fungal vaccine development | 1 | Investing.com | ||
01.10. | Appili erhält NIAID-Vertrag über 3,6 Millionen US-Dollar zur Entwicklung eines Pilzimpfstoffs | 4 | Investing.com Deutsch | ||
APPILI THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
01.10. | Appili Therapeutics Inc.: Appili Therapeutics and its Partner Vitalex Biosciences Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal Vaccine VXV-01 | 52 | GlobeNewswire (Europe) | Awarded contract base period of US$3.6 million to fund vaccine manufacturing with additional option periods to advance development through Phase 1 trials Submitted up to US$97 million in additional... ► Artikel lesen | |
24.09. | Appili Therapeutics Inc: Appili Therapeutics holders approve AGM resolutions | 1 | Stockwatch | ||
23.09. | Appili Therapeutics shareholders approve all resolutions at annual meeting | 2 | Investing.com | ||
23.09. | Appili Therapeutics Inc.: Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders | 69 | GlobeNewswire (Europe) | HALIFAX, Nova Scotia, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for... ► Artikel lesen | |
15.08. | Appili Therapeutics GAAP EPS of -$0.01 | 1 | Seeking Alpha | ||
14.08. | Appili Therapeutics Inc.: Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2026 | 130 | GlobeNewswire (Europe) | Submitted two additional U.S. government funding proposals during the quarter, bringing the total proposals to US$137 million Accepted as a new member of U.S. Medical CBRN Defense Consortium, strengthening... ► Artikel lesen | |
06.08. | Appili Therapeutics Inc: Appili releases tularemia vaccine results | 1 | Stockwatch | ||
06.08. | Appili Therapeutics Inc.: Appili Therapeutics and Colleagues Publish Manuscript Demonstrating Efficacy of ATI-1701 Tularemia Vaccine | 1 | GlobeNewswire (USA) | ||
26.06. | Appili Therapeutics Inc.: Appili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results | 940 | GlobeNewswire (Europe) | LIKMEZ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL re-launched and commercial sales ongoing Five U.S. government proposals submitted, totalling up to US$125 million HALIFAX, Nova Scotia... ► Artikel lesen | |
30.05. | Stocks in Play: Appili Therapeutics Inc. | 1 | Baystreet.ca | ||
30.05. | Appili Therapeutics Inc.: Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc. | 304 | GlobeNewswire (Europe) | NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, May 30, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink:... ► Artikel lesen | |
20.05. | Appili Therapeutics Inc: Appili to receive termination fee from Aditxt | 1 | Stockwatch | ||
19.05. | Aditxt to terminate arrangement agreement with Appili Therapeutics | 1 | Seeking Alpha | ||
19.05. | Appili Therapeutics Inc.: Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc. | 273 | GlobeNewswire (Europe) | NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, May 19, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink:... ► Artikel lesen | |
01.05. | Appili Therapeutics Inc.: Appili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to Tularemia | 1 | GlobeNewswire (USA) | ||
28.04. | Appili Therapeutics Inc: Appili Therapeutics granted patents in U.S., Mexico | 1 | Stockwatch |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
ABBVIE | 199,40 | -0,10 % | Dividendenbekanntmachungen (15.10.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABBOTT LABORATORIES US0028241000 0,59 USD 0,5082 EUR ABBVIE INC US00287Y1091 1,64 USD 1,4127 EUR ABBVIE INC CDR CA00288K1084 0... ► Artikel lesen | |
INNOCAN PHARMA | 9,850 | -1,50 % | Innocan Pharma Corporation: Das Patent für die liposomale CBD-Injektionstechnologie (LPT-CBD) wurde in Japan erteilt | Innovative Behandlung chronischer Schmerzen erhält Zulassung für IP-Schutz in Japan, dem drittgrößten Pharmamarkt
weltweit
Herzliya, Israel und Calgary, Alberta - 15. Oktober... ► Artikel lesen | |
TAAT GLOBAL ALTERNATIVES | 0,136 | -100,00 % | CSE Bulletin: Suspensions - Blender Bites Limited, TAAT Global Alternatives Inc. | Toronto, Ontario--(Newsfile Corp. - Le 16 mai/May 2025) - Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as... ► Artikel lesen | |
TONIX PHARMACEUTICALS | 16,800 | -1,18 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals to Present Poster on Tonmya at the 2025 American College of Rheumatology (ACR) Convergence | ||
AEQUUS PHARMACEUTICALS | 0,005 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 13.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 13.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 13.05.2025ISIN NameUS2310828015 CUMULUS... ► Artikel lesen | |
SHANGHAI PHARMACEUTICALS | 1,340 | 0,00 % | SH PHARMA (02607): NOTICE OF BOARD MEETING | ||
CIPHER PHARMACEUTICALS | 9,100 | 0,00 % | Cipher Pharmaceuticals is a buy, this analyst says | ||
BAYER | 27,225 | -0,48 % | Fast 150 % Kurschance! Plug Power, Bayer, Planethic Group Aktie | Bietet sich bei der Planethic Group (vormals Veganz Group) die Kaufchance des Herbstes? Analysten sehen jedenfalls über 100 % Kurspotenzial. Die jüngste Korrektur scheint übertrieben und lockt zum Einstieg.... ► Artikel lesen | |
NOVO NORDISK | 45,890 | -3,05 % | Übernahmefieber und KI-Chance: BioNTech, Novo Nordisk, PanGenomic Health Aktie | Übernahmefieber im Pharma- und Biotech-Bereich. Novo Nordisk hat nach der angekündigten Milliardenübernahme in den USA den nächsten Deal gemeldet. Die Dänen sehen ein mögliches Best-in-Class-Therapeutikum... ► Artikel lesen | |
MERCK KGAA | 113,90 | -0,78 % | DAX-Check LIVE: Drägerwerk, Hypoport, Merck, Rheinmetall, SAP, Sartorius Vz. im Fokus | Zur Wochenmitte hat sich der deutsche Aktienmarkt eher verhalten präsentiert. Nach einem freundlichen Auftakt drehte der DAX im Verlauf ins Minus und beendete den Handel 0,23 Prozent schwächer bei 24.181... ► Artikel lesen | |
BRIGHT MINDS BIOSCIENCES | 69,19 | 0,00 % | Bright Minds Biosciences stock maintains Buy rating at H.C. Wainwright | ||
HARROW | 40,810 | 0,00 % | Harrow Aktie - 40% profitables Wachstum mit Augenheilkunde | Der US-amerikanische Pharmakonzern Harrow Health (NASDAQ: HROW) steht zunehmend im Fokus von Anlegern, die nach profitablen Wachstumswerten im Gesundheitssektor suchen. Anders als viele Biotech-Unternehmen... ► Artikel lesen | |
AQUESTIVE THERAPEUTICS | 7,035 | 0,00 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Broadens Patent Estate for Anaphylm | New patents extend protection for Anaphylm into 2037Anaphylm (dibutepinephrine) Sublingual Film, if approved by the FDA, will be the first and only oral medication for the rescue treatment of severe... ► Artikel lesen | |
METSERA | 52,95 | 0,00 % | Metsera, Inc.: Metsera Reports Positive Phase 2b Results for First- and Best-in-Class Ultra-long Acting GLP-1 RA Candidate MET-097i, Enabling Rapid Transition into Phase 3 | Placebo-subtracted mean weight loss up to 14.1% after 28 weeks with no plateau Potential for best-in-class tolerability with minimal diarrhea signal, 13% nausea, and 11% vomiting High study and... ► Artikel lesen |